Drug intelligence / Profile preview

Depex-P

Development stage
Unknown
Lead developer
Alde Medi Impex
Modality
Small Molecules
Administration
Oral
01

Overview

Depex-P is a combination syrup formulated with chlorpheniramine maleate, dextromethorphan hydrobromide, and phenylephrine hydrochloride. It is developed by Alde Medi Impex and is marketed for the relief of symptoms associated with the common cold, allergies, and upper respiratory tract infections, such as dry cough, nasal congestion, runny nose, and sneezing. Chlorpheniramine maleate is a first-generation antihistamine that acts as a competitive antagonist of the histamine H1 receptor, reducing allergic symptoms. Dextromethorphan hydrobromide is an antitussive agent that acts as a sigma-1 receptor agonist and a non-competitive NMDA receptor antagonist, suppressing the cough reflex in the brain. Phenylephrine hydrochloride is a selective alpha-1 adrenergic receptor agonist that acts as a decongestant by causing vasoconstriction in the nasal passages, thereby reducing swelling and congestion.

Brand names
Depex-PDepex-P syrup
Other names
CPM + dextromethorphan + phenylephrineCPM plus dextromethorphan plus phenylephrinechlorpheniramine + dextromethorphan + phenylephrinechlorpheniramine maleate + dextromethorphan hydrobromide + phenylephrine hydrochloridechlorpheniramine maleate plus dextromethorphan plus phenylephrine syrup
02

Targets

ADRA1A (α1A)ADRA1B (α1B)ADRA1D (α1D)NMDAR (Glutamate receptor ionotropic, NMDA)HRH1 (Histamine H1 Receptor)SIGMAR1 (Sigma non-opioid intracellular receptor 1)

Beyond the preview

Go deeper on Depex-P.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Depex-P.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call